Used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients. It is a potent integrase strand transfer inhibitor (INSTI) that blocks the viral integrase enzyme, preventing HIV-1 from integrating its genetic material into the host cell DNA. This action reduces viral load and helps maintain immune function. Bictegravir sodium is commonly formulated in single-tablet regimens, offering a convenient once-daily dosing option with high efficacy and a high barrier to resistance. It is suitable for treatment-naïve patients and those switching from stable regimens without prior resistance to integrase inhibitors.